CBD Forum by Chow420

Go back
Refer
$20
Refer
Get $20 in Chowcash when you refer friends, stores, and brands to Chow420. Your friends also get $20 towards their first purchase when they accept your invitation.
Login to Refer

Hemp News, Laws & Product Updates

A curated news hub focused on hemp regulation and policy changes, cannabinoids (CBD/Delta-8/Delta-9/hemp-derived THC), lab testing and COAs, product safety, brands, and industry trends.

  • Federal & State Hemp Laws
  • THC Policy
  • CBD / Delta-8
  • Compliance
  • Lab Testing (COA)
  • Product Safety
  • Industry & Brands
Back to Chow420
https://hightimes.com/

The Other Kind of Drug Test

There’s a longstanding and popular belief amongst our community that you can’t trust anyone who doesn’t get high. That a person in the circle who passes on the joint is an automatic flag on the field and a fifteen-yard penalty. Regardless of if you’re part of the industry, the community, or just a casual consumer, it’s an easy idea to understand. Hell, we’ve all seen Gordon Ramsay lambasting a chef for not tasting their food and it’s tough to imagine buying steaks from a butcher who passes up BBQ. Not to mention that, in the cannabis world, we put a lot of stock behind how well a person holds their smoke. However, what used to represent a sort of marijuana-mason’s handshake has over the years become a method of assuming a person’s passion for the plant or their craft. We hold a degree of scrutiny over those at the party who pass on a puff. So what about if someone used to partake but stops for personal or health related reasons? Should they experience the same scrutiny? Do they experience a loss in relationship with the plant? Does their work suddenly become less authentic? I mean, to give the other half of the chef argument from earlier, plenty of cooks taste the soup and still have it come out tasting like Campbell’s. We respect a person passing the pipe for a tolerance break, but there’s a different kind of feeling when someone lets that break stray into a hiatus. I don’t want to say that it’s easier to take a break as a casual consumer, but that taking one when you’re living in the deep end of the pool draws attention from the other swimmers, and never the good kind.  What I’ve started to realize is that this reflexive litmus test we keep giving each other now disregards a basic concern for each other’s well-being. There are a lot of personal and health-related reasons a person might want to take a break from weed but still enjoy the fellowship of community. I mean, let’s face it, this weed game is like underwater living: there’s always an element of pressure surrounding you and it will fill all the available space if you let it. This pressure contributes to keeping up a status quo instead of stopping to address issues that can have a huge effect on our lives. I’ve had a lot of friends over the years who’ve admitted to me that they’re not smoking but don’t want to tell people so it doesn’t become a thing. Lately, I’ve seen more of a rise in people needing to take a break from smoking to work on themselves and this leading to them exploring other connections to weed while focusing on their own health. The whole thing got me questioning if we aren’t being a little quick to judge and if, like so many things related to this plant, this correlation between smoking and inclusion is no longer so cut-and-dry (no pun intended).  Much of this preconception seems rooted in that old-school “are they a cop” mentality—the idea that, for starters, we need to see you get high in order to know you’re one of us. When the green rush spread over California, we used this litmus test to help identify individuals who were only hanging around for the money. Drinkers and non-drinkers alike will tell you they feel like a sore thumb when they’re at a bar without a glass. So anyone who wouldn’t hit the joint or didn’t know how to hold one was seen as a cash-grabbing outsider, (though it didn’t really prevent them from collecting the checks). I think most of us can agree we’ve long used smoking as a way to break the ice but much in the same way the business world treats booze, the industry and the scene too often takes how many dabs a person takes, or blunts they smoke as a reading of acumen instead of a reflection of their tolerance. I guess what I’m saying is, when someone says they don’t smoke, we might want to respectfully ask why instead of inquiring if the DMV had to list baby lungs on their driver’s license. If you’re unsure as to if by not smoking someone is severing a connection to the source, you have only to look at Bask Triangle Farms in Spain, whose owner told me how, after seventeen years of smoking weed, he was suddenly faced with serious health issues and some even more difficult choices. Doctors told him that despite multiple surgeries on his lungs he could no longer smoke cannabis. The pill was a tough one to swallow for a person who’s been growing and smoking since they were in high school. Despite this, he’s kept a thriving connection to his work and his brand has gone on to dazzle judges at Europe’s Spannabis Champions Cup, Seville Cannabis Cup and Secret Cup Bizkaia. When I asked him if he felt quitting smoking had taken anything away from his growing or breeding, he said, “there is no one exclusive way to test the work of a breeder and hashmaker.” He described how, over time he’s developed other ways to connect to the plant, through edibles and even low-temp dabs and that none of it has severed his joy for the work. The journey has shown him that the inherent risks involved in smoking weed aren’t part of his connection to cannabis. When asked if doing away with joints and bongs has caused him to miss the next big strain in his R&D room he said absolutely not. While he personally sees maintaining some kind of weed in your system integral to staying on your game, as he put it, “there are many ways to understand, connect with, or use cannabis.” Looking at the list of multiple award-winning in-house crosses, I’d say he has a point. Another example is The Real Cannabis Chris, a California grower and hashmaker who took a step back from smoking for over three years to work on his relationship with himself and others. After years of smoking and dabbing, he developed a social anxiety that made it difficult to connect with strangers and even loved ones. Chris talked about how, after making the difficult choice to focus on mental health, what started as a tolerance break grew into almost a year and that’s when he discovered that all energy he had been putting into smoking transferred into growing, both as a person and better plants. “I was more present in my life, in my relationships and in my garden and this led to asking more questions and looking for more answers.” This is how he developed the next phase of his connection to the plant. As more time passed, he began to notice all these new smells in the buds and in the jars. This evolved connection to his plants, combined with the one he shares with the team who help grow and taste the work, is what he attributes to creating a kitchen that has now won a slew of first prize wins, judge’s picks, and a chance to travel to Thailand to compete with players from around the world. Arguably one of the most awarded hashmakers of 2023, he points out that it wasn’t until well into this sabbatical that he began winning multiple accolades for his work. When it comes to judging someone by their craft, well that’s the easy part. Things move awfully fast around here and if a person’s work doesn’t hold up, the community will absolutely let you know. When asked if they’ve received criticism from comrades or contemporaries for passing on the joint, Chris commented, “at first glance it’s easy to throw shade without an understanding. People might think I’m just in it for the money but what they don’t know is that I’ve been at this since i was basically a kid.” He mentioned how after a podcast joked that he hadn’t smoked in a decade, he received a ton of comments that were almost attacking his credibility. The situation prompted him to film a video discussing his three-and-a-half year break relating to a journey of mental health and the comments transformed into an overwhelming amount of responses from people who were thinking about taking their own break but wanted to know how he maintained his connection to the plant and the people while not puffing. Bask Triangle echoed a similar sentiment, “In this industry there is always someone who wants to speak badly about others and will use any reason to do so. But we should not waste time on such trifles and we must continue doing what each person likes the most, without paying attention to what others say.”  These are just two examples of how an individual can take a break or stop smoking altogether and discover new connections that enhance and compliment their work with cannabis while also focusing on something we take for granted: health. It’s something that we should really give more space to, and if that leads you to a different place in your cannabis journey, I’ll still welcome you around the water cooler. I think we’ll probably always have a hiccup with people who are in the room but don’t have a connection to growing, tending, or consuming cannabis but if you want to know if a person choosing to go off the sauce matters, maybe ask them the follow-up of how they’re doing. I’ve learned a lot about not making split judgements on someone choosing not to smoke or to take a break and that surviving alongside this plant and the mileage this life puts on the car often runs deeper than what you see out at the session. As far as judging a person by how much of their jar they smoke when they sit down, why not see how much of it you smoke instead.

https://hightimes.com/

The Beatles’ Psychedelic Painting ‘Images of a Woman’ Auctions for Over $1.7M at Christie’s

In 1966, all four members of The Beatles painted a piece in oil and watercolor on Japanese paper, “Images of a Woman,” at the peak of their fame while on tour in Japan. The piece went up for auction Feb. 1 at Christie’s New York in New York City, and sold to a buyer with astounding results, for over $1.7 million, after a lively bidding round. The high-end auction features lavish, upscale art dating back centuries. The Beatles classic lineup—John Lennon, Paul McCartney, George Harrison, and Ringo Starr—all painted a quarter of the piece and signed the painting. Bidding for “Images of a Woman,” 54 cm x 78 cm, began at $400,000-600,000, and the final price the buyer will have to pay is $1,744,000. It’s likely the only painting with work contributed by all four band members. Christie’s posted a 12-photo gallery showing the Fab Four painting it. The latest event at Christie’s New York is a rock ‘n’ roll collector’s dream: “The Exceptional Sale,” also features priceless art and memorabilia like a gold-colored crocheted vest that was worn by Janis Joplin (bidding started at $50,000), and Elvis Presley’s 1965 guitar made by The Fred Gretsch Manufacturing Company, used during his 1969 Las Vegas, Nevada residency (bidding started at $350,000). David Gahr photographed Joplin wearing the vest on the roof garden of the Chelsea Hotel in 1970. Joplin’s vest eventually ended on the cover of the November 1976 issue of Rolling Stone and was one of her favorites pieces to wear. High Times learned that bidding for The Beatles painting on Thursday got intense, with about three in the room holding out to the end, among many other bidders that called in. Organizers were pleased with the overall results. “It was great to see The Beatles topping the charts again with this amazing auction result,” The Head of Christie’s Exceptional Sale, Casey Rogers, told High Times. “There’s nothing like this painting. It’s a work of art. It’s a piece of memorabilia. We told that story, and the market responded with strong competition from bidders in the room and on the phone.” Keep in mind that The Beatles—defunct for over 50 years—topped the charts months ago in November 2023 with “Now and Then,” a song they finished using a little help from AI. The event was designed only for serious collectors with money. “The Exceptional Sale” featured everything from an elegant 18th century candelabra to a Wedgwood & Bentley sculpture of the infant Hercules in black basalt. Other notable items date back further. The French and English furniture masterpieces include a pair of tabourets belonging to Empress Joséphine de Beauharnais, and a Louis XIV Gobelins tapestry formerly in the collection of William K. Vanderbilt (1849-1920). Psychedelics and cannabis have a well-known impact on the music (and art) of The Beatles. Lennon and Harrison, along with their wives, were the first to take LSD in 1965, after being dosed by a dentist. They would become part of the profound impact psychedelics had on Western counterculture and music. This painting shows how psychedelics impacted their art. The four painted “Images of a Woman” just two months after recording Revolver, perhaps one of their most psychedelic, and most respected albums, taking a 180-degree detour from their early pop era that was based on radio-friendly love songs. At the time when “Images of a Woman” was painted in 1966, “Beatlemania” was at its peak. The moment the Fab Four stepped off their plane at Haneda Airport in Tokyo, Japan on June 29, 1966, The Beatles used a “moment of calm at a tumultuous time,” to create a piece of abstract art with some of the countless art supplies fans had given them. While Beatlemania was strong in Japan, so was the politically nationalist Japanese, who saw The Beatles as “emblems of an invasive Western culture,” and completely rejected them, and the band was confined for most of their five-day tour in Japan to the presidential suite at Tokyo’s Hilton Hotel. They received death threats from Japanese who rejected Western culture and considered the band to be a representation of that. “I’ve never seen so many people guarding us,” drummer Ringo Starr said at the time. They took a piece of Japanese watercolor paper and put it on a table, then placed a ceramic lamp in the center, where they would sign their names. Lennon in particular was interested in art. In 1957, young Lennon attended the Liverpool College of Art where he met former Beatle Stuart Sutcliffe. He continued to dabble in art his whole life. High Times reported on another Beatles-related art piece that has a connection with cannabis. Antiques Roadshow season 46, episode 2, featured a cartoon depicting McCartney being searched for pot by airport customs and with an autograph from the singer. Christie’s is an auction house founded in 1766 by James Christie. The piece sold at Christie’s New York is probably the most valuable visual art the band has created. 

https://hightimes.com/

Texas Attorney General Sues 5 Cities Over Weed Decriminalization

Texas Attorney General Ken Paxton on Wednesday filed lawsuits against five cities that have passed marijuana decriminalization measures. The legal action was filed against the cities of Austin, San Marcos, Killeen, Elgin, and Denton “for adopting amnesty and non-prosecution policies that violate Texas laws concerning marijuana possession and distribution,” according to the attorney general’s office. In 2022, the five cities each adopted ordinances or civic policies that instruct police officers not to enforce state laws prohibiting the possession or distribution of cannabis. After filing the lawsuits this week, Paxton said that such policies are prohibited by the Texas Local Government Code, which bars municipal and county governments from adopting “a policy under which the entity will not fully enforce laws relating to drugs.” “I will not stand idly by as cities run by pro-crime extremists deliberately violate Texas law and promote the use of illicit drugs that harm our communities,” Paxton said in a statement on Wednesday. “This unconstitutional action by municipalities demonstrates why Texas must have a law to ‘follow the law.’ It’s quite simple: the legislature passes every law after a full debate on the issues, and we don’t allow cities the ability to create anarchy by picking and choosing the laws they enforce.” The attorney general also noted that under Article 9, Section 5 of the Texas Constitution, it is illegal for municipalities to adopt ordinances that are not consistent with the laws enacted by the Texas Legislature. With the lawsuit, Paxton has asked the district court to overturn the city ordinances and instruct local officials to enforce state law. Julie Oliver, executive director for Ground Game Texas, a group that works to advance progressive issues including local marijuana decriminalization ballot measures, said that the attorney general’s legal action seeks to undermine the right of Texans to govern themselves at the local level. “Ken Paxton’s lawsuits represent an anti-democratic assault on the constitutional authority of Texas Home Rule cities to set local law enforcement priorities,” Oliver told local media. “In each of the cities sued, a supermajority of voters adopted a policy to deprioritize marijuana enforcement in order to reduce racially biased law enforcement outcomes and save scarce public resources for higher priority public safety needs.” In Denton, a city of about 140,000 people in the Dallas-Fort Worth metropolitan area, voters passed an initiative to decriminalize misdemeanor marijuana offenses in November 2022. The ballot measure received the approval of more than 32,000 votes and the election marked the highest voter turnout recorded in the city’s history. “This ordinance has now received more votes than any council member or mayor in the history of Denton,” Nick Stevens from Decriminalize Denton, a grassroots organization behind the ordinance, told the Denton Record-Chronicle after the election in 2022. “We’re ecstatic that Republicans, Democrats and independents came together to reclaim their power in the city.” Denton’s marijuana decriminalization policy, however, has not yet been fully implemented and the city’s police have still been issuing citations for misdemeanor marijuana offenses. In June, the Denton City Council considered an ordinance that advocates said would have strengthened the measure approved by voters but voted 4-3 against the proposal. The attorney general’s lawsuit is partly based on HB 2127, a bill passed last year that restricts so-called home rule authority. Attorneys for cities including Denton, San Antonio, Waco and Plano that filed suit against the law last year explained that home rule allows local governments “to create policies that address local concerns that vary from jurisdiction to jurisdiction based on many factors such as demographics, population density, environmental concerns and public safety issues.” But Stevens said that HB 2127 does not cover the city marijuana decriminalization measures because it states that it only applies to municipal or county codes involving agriculture, finance, insurance, labor, natural resources and occupations. “Ken Paxton should read this law before wasting Texans’ tax dollars with another frivolous lawsuit that distracts from the work we have done to deliver for the people of Denton,” Stevens said. Ground Game Texas is currently sponsoring a campaign to decriminalize marijuana in Dallas. Known as the Dallas Freedom Act, the measure would end most arrests and citations for Class A and Class B misdemeanor marijuana possession. The proposed ordinance, which is similar to the one passed in Denton, would also require city leaders to report on cannabis enforcement and forbid the use of city funds for laboratory testing to distinguish hemp from marijuana. “The Dallas Freedom Act is a dynamic initiative that will reduce unnecessary arrests, address racial disparities in marijuana enforcement, and save millions of dollars in city and county resources for much-needed public safety programs,” Tristeza Ordex, campaign manager of Ground Game Texas, said in a statement about the proposal.

https://hightimes.com/

Ireland Government Approves a Nine-Month Delay on Cannabis Legalization Vote

The Irish government has delayed on discussing a bill that would legalize cannabis possession for nine months. A report submitted by the Citizens’ Assembly on Drugs Use completed its review of Ireland’s current drug policies in October 2023, and released a final report on Jan. 25, which includes 36 recommendations for prioritizing marginalized groups and communities, focusing on prevention and recovery, and more. On Jan. 24, 2024, one day prior to the release of the report, Taoiseach (TD) Leo Varadkar (who holds a position similar to that of a prime minister) attended a Dáil Éireann parliament hearing and joined legislators in discussing the path forward. “The chairperson of the Citizens’ Assembly stated there is no time to waste. No time to waste, taoiseach. If it saves one life, literally one person, if that can save one life, then it’s worth changing course in relation to criminalizing people,” said Gino Kelly, a TD for the People Before Profit political party, said in the hearing on Jan. 24. “So my question is: will the government take the recommendations—and now [not only] take the recommendations in relation to policy? But the key thing in relation to that report was legislative change. We have [had] the misuse of drugs act since [the] 1970s, criminalizing people, sending people into the criminal justice system, sending people to the courts, jailing people…It doesn’t work, taoiseach.” Kelly continued that the country’s prohibition has “stigmatized, marginalized and criminalized not only individuals, but communities across the country.” He added that if the government decided to accept the commission’s report, that “we can change the course, and we can actually save lives and take people out of the criminal justice system.” Varadkar responded, stating that decriminalization should come with other policies as well, and that multiple committees should help manage cannabis reform. “We shouldn’t just try to copy models in other countries,” he added. On Jan. 30, Varadkar proposed to delay the cannabis bill vote by nine months, which would halt progress until at least October. He also called for the creation of a special committee. “One of the things the special committee will have to tease out is what does decriminalization really mean in a legal context—under an Irish context?” said Varadkar. “Does that mean that’s not an offense at all? Doesn’t [that] mean that it’s not an indictable offense? Does [it] mean that it’s an offense without a penalty? Is there something like penalty points? Or does it actually mean that, up to a certain amount of each particular substance, that would not be illegal?” “In my view, drug use and misuse by individuals should be seen primarily as a public health issue and not a criminal justice matter,” Varadkar continued. “I certainly think that shaming people and blaming people and criminalizing people isn’t an effective policy.” Other legislators in support of ending prohibition and moving Ireland forward in drug reform are disappointed in the delay. “The government has announced they will try to delay our Bill to decriminalize possession of small amounts of cannabis by nine months,” said TD Paul Murphy on X. “That is simply an attempt to kick the can down the road. They talk about a health led approach to drugs. Now it’s time to walk the walk. On Jan. 31, the government approved the nine-month delay. “Passing this bill today would have allowed it to go to the committee stage where we could have had this conversation and actually started taking meaningful first steps towards realizing the recommendations of the citizens assembly,” Kelly said on X. “Instead the government chose to do nothing.” The bill was introduced in November 2022 by Kenny, Murphy, Mick Barry, Brid Smith, and Richard Boyd Barret. On an illustrated line of progress on the Ireland bill page, the Misuse of Drugs (Cannabis Regulation) Bill 2022 is only on step 2 of 11. Next it must be discussed by legislators to reach the Committee Stage, Report Stage, and Final Stage in Dáil Éireann parliament, which must also be discussed in the upper house, called the Seanad Éireann, as well. The Citizens’ Assembly on Drugs Use is made up of 100 people in total—99 general public representatives and one independent chairperson—who are selected at random. In 2023, the assembly spent five previous meetings listening to both experts and first-hand accounts from people suffering from addiction. In October 2023, the assembly voted on recommendations to send to legislators—39 chose to vote for approaching drug policy from a public health standpoint, while 38 voted to implement legalization and regulation of cannabis. Had the latter received one more vote, the assembly would have instead recommended legalization. “This indicates an appetite to completely overhaul the State’s cannabis policy, including full legislative decriminalization [sic], regulatory implementation around sale and supply alongside the repeal of prior criminal convictions for cannabis use,” the assembly announced in a statement at the time. Medical cannabis has been legal in Ireland since June 2019, but it took years for the country to open its first medical cannabis clinic. It finally happened in November 2023, and the clinic now serves both patients admitted to the Medicinal Cannabis Access Programme, as well as others. Currently, only three conditions qualify for medical cannabis: spasticity associated with multiple sclerosis, intractable nausea and vomiting associated with chemotherapy, and severe treatment-resistant epilepsy.

https://hightimes.com/

Arizona Bill Would Legalize Psilocybin Service Centers, Add to Current Research Efforts

As Arizona lawmakers push for increased psilocybin research, some are looking to take things a step further by joining the ranks of other states that have ushered in legal psilocybin therapy. A group of nine bipartisan lawmakers in the state are sponsoring the newly introduced bill which would legalize psilocybin service centers, allowing those in Arizona to undergo therapy with the psychedelic substance under medical supervision, according to a Marijuana Moment report.  The bill would allow the Department of Human Services (DHS) to license these centers and would also establish the Arizona Psilocybin Advisory Board. The board would include members appointed by the governor and legislative leaders, like representatives of the attorney general’s office and DHS, military veterans, first responders, scientists with psilocybin experience and physicians, among other potential groups. Following in the footsteps of other states that have legalized psilocybin therapy, the board would need to establish training criteria for those working in psilocybin service centers and would also make recommendations on how the law is implemented while studying the science and policy developments related to psilocybin and other psychedelics. Board members would also be required to submit an annual report by July 31, 2025 and each year after regarding the status of “medical, psychological and scientific” studies surrounding the safety and efficacy of psilocybin. Members would also be required to report on a “long-term strategic plan” to ensure psychedelic-assisted therapy remains “safe, accessible and affordable” to those over 21. Medical directors of the therapy centers would be required to complete at least 132 hours of training under the approved program, including lessons on the historical and traditional use of psychedelics, safety and ethics, facilitation and preparation, administration and integration.  If passed, it would likely still be some time before Arizonans could expect to utilize the psilocybin services, however — the bill notes that the DHS would need to start accepting applications for the centers by Jan. 1, 2026. While the DHS would need to create rules for the program, the department would not be allowed to require specific eligible conditions for the services. The bill would also provide a significant boost to the state’s existing law focused on psilocybin research. Last year, the research was approved as part of an appropriations package specifically mandating further study into the medical potential of psilocybin pertaining to conditions like post-traumatic stress disorder (PTSD), depression, anxiety, long COVID symptoms and substance misuse disorder. The legislation puts $5 million in funding toward the research, and unlike many other previous studies, Arizona’s prospective research would not utilize lab-produced psilocybin. Rather, it would look at the use of whole mushrooms. More recently, an Arizona House committee approved another bill meant to protect the funding from being redistributed while the state deals with a budget deficit. Passing in an 11-3 vote, the legislation keeps the psychedelic research funds from going elsewhere until at least July 2026 so long as it gains final approval. Without the new legislation, research appropriations were set to expire this summer, which advocates argued was not enough time to properly conduct the research. Without the deadline extension, Dr. Dani Cabral, the principal investigator at IMA Clinical Research, said, “We are in a position here where we have $5 million, and few researchers will be awarded these funds, and they will have four months to complete a random control trial.” Sponsor Rep. Kevin Payne (R) similarly chimed in, pointing out that the research under the current timeline is essentially not possible. “What’s going to happen is they’re going to be halfway through the study and the money is going to run out and they’re not going to get paid at all,” he said. “So there won’t be anybody doing any studies unless we get this bill done.”

https://hightimes.com/

Former NFL Stars Hint at Presidential Bid With Weed Platform

Two-time Superbowl Champion Jim McMahon and All-Pro offensive lineman Kyle Turley are hinting at a run for the White House with a campaign built on passing a banking bill for legal marijuana businesses and creating awareness for the benefits of cannabis, according to a report from Fox Sports. McMahon, who played quarterback for the Chicago Bears, and Turley, a first-round pick by the New Orleans Saints in the 1998 NFL draft, are co-founders of the cannabis brand Revenant along with fellow professional football player Eben Britton. According to the company website, a “mutual respect and understanding of the healing principles the cannabis plant provides brought these gentlemen together and fuels [their] desire to share it with the world.” Last week, Turley visited New Hampshire to share his advocacy with Republican presidential candidate Nikki Haley and Democrat Dean Phillips, who has launched a long-shot bid to overtake President Joseph Biden in the race for the 2024 Democratic presidential nomination. During the visits, Turley reportedly talked up the benefits of cannabis and urged the candidates to support the Secure and Fair Enforcement and Regulation (SAFER) Banking Act, legislation that would give regulated cannabis companies access to traditional business banking services. Now, McMahon is teasing a potential run for president with Turley as his running mate, according to the Fox Sports report, with a platform based on cannabis advocacy and support for the marijuana banking bill. “We’re trying to get the message out about this cannabis plant and about fair banking,” McMahon told Fox News Digital. “We’re trying to bring awareness, not only to the cannabis industry but things that are going bad in this country. We’re going to make a little bit of noise. We might get some votes just for the cannabis part. We’re gonna have some fun with it. We’re gonna try and grow our brand and make people aware about this plant. We’ll see what happens.” The SAFER Banking Act was approved by the Senate Banking Committee in September and advanced for consideration by the full Senate. The bill is a revamped version of the Secure and Fair Enforcement (SAFE) Banking Act, a bill to provide cannabis companies access to traditional banking services that was passed by the House of Representatives seven times.  Under current federal law, providing financial services to cannabis companies is strictly regulated, leaving many businesses—particularly small, independent operators—without access to bank accounts, credit card processing and other financial services. As a result, many businesses operate exclusively or largely in cash, leaving operators and their customers and staff vulnerable to crime.  The SAFER Banking Act would remove the barriers to financial services for cannabis companies. Financial institutions would not be required to offer banking services to cannabis companies, but the bill discourages banks and credit unions from denying such services based on “personal beliefs or political motivations.” The measure also directs the U.S. Treasury’s Financial Crimes Enforcement Network to amend previous guidance on cannabis banking services within six months and for “depository institutions” to comply with the agency’s new regulations. In addition, to cannabis banking and advocacy, McMahon shared other themes of the hypothetical presidential campaign, touching on immigration, homelessness, taxation and spending policy. “I’d close the damn borders for one and then go find all the people that got in here illegally,” he said. “It’s ridiculous. We’re paying all this money as taxpayers, and it’s not helping us at all. We’re sending it all overseas, you know. Who knows where we’re sending it, but it’s not being used here in the states. “You look at California. They get the most money every year for homelessness, and they got the worst homeless population in the country or probably the world. There’s just so many things going wrong. We got to just stop the crazy spending and printing money and close our borders and let’s clean house.” McMahon played 15 years as an NFL quarterback, leading the Chicago Bears to the Superbowl championship following the 1985 season, later winning another ring with the Green Bay Packers. His experience with the pain and recovery associated with playing professional football led him to advocate for the NFL to change its policy surrounding cannabis use. “They need it for physical recovery,” McMahon recently told Forbes. “There’s no doubt about it. I mean, it’s the only neuroprotectant that has a patent on it. Why can’t they freely use that, rather than things that only mask the pain? That’s all they do. They don’t heal the body, they don’t help the body. They ruin your body, you get addicted to them, and they kill people, whereas cannabis has never killed anybody.” After being drafted by the Saints in 1998 and playing there for five seasons, Turley spent a year with the St. Louis Rams. A back injury prevented him from playing in 2004 and 2005, but he returned to NFL action to finish his career with two seasons on the Kansas City Chiefs. He has been a vocal cannabis advocate since he retired from the NFL and has also lobbied the league to lift its ban on cannabis.

https://hightimes.com/

19 Charged in Connection to Southern California Drug Trafficking Organization

Department of Justice indictments against an accused drug trafficking organization operating out of Southern California were unsealed Tuesday, revealing a vast criminal network which allegedly moved millions of dollars worth of drugs from California to Canada. According to a Department of Justice press release, the criminal network they targeted was responsible for trafficking hundreds of kilograms of cocaine, fentanyl and methamphetamine from Mexico into Los Angeles where they loaded it onto semi-trucks bound for Canada or other parts of the United States.  Various law enforcement organizations executed arrests and search warrants in Los Angeles; Sacramento, California; Miami; Odessa, Texas; Montreal; Toronto; and Calgary, Canada Tuesday morning with 30 search warrants served in Los Angeles alone. “Operation Dead Hand” as it was so dubbed by the feds was responsible for ten arrests in multiple cities across the United States and Canada. “Today’s charges and arrests across North America reflect the Justice Department’s close coordination with our Mexican and Canadian partners to disrupt international narcotics trafficking,” said Deputy Attorney General Lisa O. Monaco. “These cases provide yet another example of how our agents and prosecutors work side-by-side to uncover and dismantle organized criminal networks peddling and profiting from deadly drugs.” The many defendants charged in the two unsealed indictments are as follows: A notable name from that list is Robert Scoppa, whom the Department of Justice described as an alleged Canadian drug trafficker believed to be moving massive amounts of drugs on a regular basis with close ties to an Italian organized crime family. The other defendants were generally alleged to either be associated with Mexican crime groups involved in moving product over the southern border or handlers and dispatchers involved with a complex network of semi-truck drivers who made frequent border crossings into Canada via the Detroit Windsor Tunnel, the Buffalo Peace Bridge and the Blue Water Bridge.  “Drug trafficking is a global problem being driven by sophisticated, organized crime groups who put profits over people’s lives,” said U.S. Attorney Martin Estrada for the Central District of California. “Motivated by greed, these criminals destroy lives, devastate families, and wreak havoc in our community. But this case shows that we will collaborate with our international partners to bring these criminal networks to justice. Those who traffic in highly addictive and dangerous drugs will be held accountable.” Of the list of those indicted, 10 were arrested Tuesday, two were already in police custody and seven are considered to be fugitives. Those seven are as follows:  All those indicted face maximum penalties ranging from 40 years to life in prison. This organization has been accused of trafficking up to 845 kilograms of methamphetamine, 951 kilograms of cocaine, 20 kilograms of fentanyl, and 4 kilograms of heroin. The wholesale value of these drugs was estimated by the Department of Justice to be between $16-28 million and around $900,000 in cash was seized during this operation.  “Until today, the organized members of this conspiracy operated with impunity throughout the many thousands of miles that comprise the North American continent, poisoning communities along the way,” said Assistant Director in Charge Donald Alway of the FBI Los Angeles Field Office. “The strength of this partnership cannot be overstated. The agents and detectives on this case did an outstanding job of pooling resources and worked seamlessly across borders toward a mutual goal of putting this massive drug pipeline out of business.”

https://hightimes.com/

Veteran Oliver Carlin on a Journey To Help Spread Awareness With His Curative Mushrooms

Curative Mushrooms, a grow kit solution company owned by a Navy-veteran-turned-entrepreneur, Oliver Carlin, has emerged as a passionate advocate for the transformative power of mushrooms.  Oliver Carlin’s interest in mushrooms sprouted from his quest for holistic health solutions. Inspired by the extensive clinical studies on various mushroom strains, he started researching its benefits, to address issues such as depression, PTSD, anxiety, and addiction. As a Navy veteran with extensive experience in fitness activities, Carlin’s transition into the world of mushrooms was marked by his commitment to share this newfound knowledge with his blogs. In 2019, he founded Curative Mushrooms to simplify the process of growing mushrooms, enabling individuals to harness their health benefits without jumping from one so-called “expert video” to another or even buying costly equipment.  Recognizing the complexity of growing mushrooms, Carlin embarked on a mission to create foolproof grow kits. Despite facing challenges and investing significant time and resources, Carlin and his team developed a kit to grow mushrooms successfully within 30 days. In 2020, Curative Mushrooms created the simplest grow kit for beginners, allowing users to receive various mushroom spore syringes. The founder has also taken a step ahead to write a book on this for people who want a handy guide.  Carlin strives to provide clarity through his blogs, acknowledging the challenges of operating within legal boundaries. His goal is to educate people on their rights and provide a safe and legal way to grow mushrooms. He believes that once they understand their rights, they will be more likely to take action and grow their own mushrooms. Curative Mushrooms offers a range of grow bags for medicinal mushrooms like Lion’s Mane, Reishi, and Turkey Tail to name a few. The company has also packaged an all-in-one kit for cultivating “happy mushrooms.” They have continually improved their products, with grow bags capable of producing, on average, up to 60 dry grams of mushrooms per grow bag. The success of Curative Mushrooms is attributed to its engaged community across platforms like X, Facebook, and YouTube. “I feel that the success of Curative Mushrooms is largely due to the support of our community. I am grateful for this and will continue spreading awareness,” expresses Carlin. He remains focused on his advocacy, sharing personal stories of how mushrooms have transformed his life via social media channels.  Oliver Carlin is launching a new podcast series on Cannabis Radio with Co-Host Josh Nelson. The podcast called The Conscious Research Project will take listeners through a journey of exploring consciousness on levels that most never think of.

https://hightimes.com/

Washington Bill Aims To Tackle Cannabis Store Robbery Spree

In a string of robberies, several cannabis retail shops have reported various tactics criminals have been using to get into their businesses in recent months. As these get worse, lawmakers are cranking up the punishments for people involved in such violent crimes. A bill proposal in Washington would tack on an extra year of jail time for people convicted of robbing a cannabis store under certain conditions. Senate Bill 6133 would allow prosecutors in the state to seek a 12-month sentence enhancement if someone convicted of robbing a cannabis store is part of a group, or if a person uses a vehicle to smash into the cannabis store, which is happening very frequently in Washington and other states, particularly on the West Coast. “We need to do something to control the problem,” state Sen. Jim McCune (R-Graham), the bill’s sponsor, said during the committee hearing. If criminals are aware of increased penalties, perhaps that will be enough to dissuade them from participating in the crimes. “I believe that the tougher the penalty, the less the crime,” said McCune. “Protecting the citizens and the pot shop owners and their employees, and overall slow down crime. Now, that’s what the bill is all about.” Under the bill, a “special allegation” with increased penalties can be made if “A cannabis retail outlet, licensed under chapter 69.50 RCW, and the defendant committed the robbery by using a vehicle to damage or gain access to the retail outlet; or A cannabis retail outlet, licensed under chapter 69.50 RCW, and the defendant committed the robbery in concert with another individual or individuals; the court shall make a finding of fact of the special allegation, or if a jury is had, the jury shall, if it finds the defendant guilty, also find a special verdict as to the special allegation.” The proposal received a public hearing on Jan. 29 before the state Senate Law & Justice committee. SB 6133 passed through the Senate Law & Justice Committee on Tuesday and now heads to the Rules Committee before it can be heard by the full Senate. High Times reported on the rise of smash-and-grab robberies taking place in not only Washington, but in Los Angeles and Oakland, California, among other places. Sometimes the criminals opt for a forklift to smash into a cannabis store—basically anything they can get their hands on that can smash through locked doors and barriers. The cash-only status of cannabis businesses inherently makes them a prime target for criminals. Washington in particular has seen an uptick in smash-and-grab style robberies of cannabis stores. In October 2022 a surveillance video from police shows a crew conducting a well-organized armed robbery of a cannabis shop in Tacoma. A car crashed into a Seattle cannabis store in September 2023, for instance, representing another smash-and-grab burglary. The video surveillance from inside the store shows a car ramming into the store full-speed, followed by hooded people running inside and grabbing cannabis and merchandise off the shelves. KING 5 reports that most recently, a stolen KIA was used to crash into a Shoreline cannabis store on Jan. 2. A group of teens and young adults call themselves the “KIA Boyz” because of how often the cars are used in robberies in the area. According to a lawsuit filed against KIA by Seattle City Attorney Ann Davison, the explosion of stealing KIAs and Hyundais started as a TikTok challenge with videos of joyrides. In Seattle from 2021-2022, thefts of KIA vehicles increased by 503%. KING 5 reports that another cannabis store called the Green Lady dispensary in Lynnwood was robbed in the same manner.  “They came through the rear side of the building in February of last year, so February 2023. And then the second hit was through the front, and that was in November of 2023,” Layla Jordan, the executive assistant at Green Lady, told KING 5.  Jordan’s Lynnwood dispensary was targeted twice over the past year, and one of the dispensary chain’s Olympia locations was also hit twice over the past year. Jordan said they have spent hundreds of thousands of dollars dealing with the aftermath of these robberies. “Anytime my phone goes off at 3 a.m., I’m like, ‘Oh no, did we get hit again?'” said Jordan. “In theory, it would help, but the people who are performing these acts, I don’t think they have any regard for the law,” said Jordan. “So, I’m not sure if it’ll make a difference. But it’s still, it’s a nice thought.” Senate Bill 6133 is one approach to convincing criminals that these crimes are simply not worth the risk.

https://hightimes.com/

Cannabeginners: What are Cannabis Alkaloids?

What does cannabis, coca leaf, and all coffee have in common? They all contain alkaloids, a powerful group of medicinal compounds found in plants around the world. While little is presently known about cannabis alkaloids, they are suspected to possess impressive medical benefits like other plant alkaloids.  Alkaloids are “one of the most common groups of chemicals that [have] medicinal properties found in plants,” commonly used alkaloids include “morphine, cocaine, nicotine, caffeine, quinine, ephedrine, and many more.” They derive their name, alkaloid, from the word alkali, chemicals that react like bases, counteracting acids. Usually found in the outer tissues of plants, the bitter flavor of alkaloids is believed to be a natural defense in plants to prevent them being eaten by herbivores, similar to cannabinoids and terpenes which both assist in preventing predation.  While cannabinoids like THC, CBD, CBG, and THCv, are oily, lipohpilic (binds to fats), and hydrophobic (do not bind to water) compounds, alkaloids are a very different class of chemicals. The biggest chemical difference between alkaloids and cannabinoids is that all alkaloids include a nitrogen atom which binds to additional hydrogen atoms. Cannabinoids, on the other hand, do not have any nitrogen atoms and contain a chain of carbon atoms, which gives them their oily character.  Despite their differences, efficient methods to extract both alkaloids and cannabinoids from plants is to simply burn the leaves or other parts that contain the chemicals, or perform a chemical extraction. These methods have been used for thousands of years for both types of chemicals; the caffeine in coffee is chemically extracted by brewing with water, cannabis is smoked, and cocaine was originally extracted through chewing or brewed as a tea.  Cannabis is a very complicated plant and “more than 500 compounds have been reported from C. sativa, of which 125 cannabinoids have been isolated and/or identified as cannabinoids.” Non-cannabinoid constituents of cannabis include “42 phenolics, 34 flavonoids, 120 terpenes and 2 alkaloids.” Though, there is some debate over the number of alkaloids which have been identified. The discovery of alkaloids in cannabis actually manages to predate the discovery of the first cannabinoid, CBN, back in 1896, by more than a decade. In 1881, the first research on the alkaloid cannabinine was presented at the British Pharmaceutical Conference, and two years later another physiologically active alkaloid, tetanocannabin, was discovered. Cannabis alkaloid research then remained dormant until the 1970s. In 1971, a group of scientists isolated four different alkaloids from cannabis, which they named cannabimines A-D. In 1975, two teams of researchers at the University of Mississippi (UMiss) identified and isolated the first spermidine alkaloid, cannabisativine, from the roots, leaves, and stems of both Mexican and Thai cultivars. The next year, the same researchers at UMiss isolated the second spermidine alkaloid, anhydrocannabisativine and showed that cannabisativine could be converted to anhydrocannabisativine.  While the cannabis alkaloids cannabisativine and annhydrocannabisativine were first discovered in Mexican and Thai cultivars, anhydrocannabisativine has since been “found in plant samples of Cannabis from 15 different geographical locations.” Just like how not every part of a cannabis plant has the same amount of cannabinoids, alkaloids are also unequally distributed around the plant. Research has repeatedly shown that, “cannabis roots are not a significant source of cannabinoids or the aforementioned terpenes, but are rich in other compounds, including … alkaloids.” So while terpenes and cannabinoids are concentrated primarily in the trichomes on the leaves, cannabis alkaloids are primarily found in the roots (but can be found in the stems and leaves as well).  While cannabis alkaloids have a lot of medical potential, the specifics of that potential are unknown. In the case of cannabisativine and anhydrocannabisativine, “no pharmacological information is available,” but it is believed that “there are several compounds in cannabis root with potential anti-inflammatory activity, including alkaloids.”  Other researchers have noted that, as a class of compounds, “alkaloids may be used as analgesics, antibiotics, anticancer drugs, antiarrhythmics, asthma medications, antimalarials, anticholinergics, bronchodilators, laxatives, miotics, oxytocics, vasodilators, psychotropics, and stimulants,” and that likely includes cannabis alkaloids. One study of cannabis alkaloids found them to “have diuretic, analgesic, anticancer, antipyretic, and antiemetic effects.” In one study, a petroleum ether solution of cannabis alkaloids and cannabinoids had “a course of action comparable to that of atropine,” a drug commonly given to reduce fluid in the respiratory tract during surgery, which “can also treat insecticide or mushroom poisoning.” It is not clear to what extent those observed effects were due to the alkaloids or the cannabinoids.  Despite being one of the most common groups of medicinal chemicals found in plants, alkaloids are some of the least known chemicals in cannabis. Early research shows that they may have strong medical benefits as part of the entourage of medicinal compounds in cannabis. 

https://hightimes.com/

Drug Maker Recalls ADHD Medicine Over Label Mixup

The U.S. Food and Drug Administration last week announced the voluntary recall of a medicine used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy after the manufacturer of the drug revealed that the wrong pills were found in packages of the medication. The recall covers one lot of the drug Zenzedi, an ADHD and narcolepsy medication manufactured by Massachusetts-based Azurity Pharmaceuticals. In a notice about the recall, the FDA noted that a pharmacist had reported finding pills of an antihistamine, carbinoxamine maleate, in a package of Zenzedi. The voluntary recall was announced by Azurity on January 24 and covers packages of Zenzedi 30 milligram tablets with lot number F230169A and an expiration date of June 2025. The recalled medication was distributed nationwide through retail pharmacies. Pharmacies and drug wholesalers have reportedly pulled the drug from their shelves to comply with the recall. Customers who purchased packages of the recalled lot of Zenzedi are urged to return any remaining pills to the place of purchase. Patients who take the mislabeled medication and have adverse reactions are encouraged to see their doctor.  The two drugs have opposite effects when taken, according to a report from CBS News. Carbinoxamine maleate is an antihistamine that is used to treat allergies and has a sedative effect on some patients, while Zenzedi, a brand name for the drug dextroamphetamine sulfate,  is a stimulant that generally increases a patient’s attentiveness. Zenzedi is used to treat narcolepsy, a sleep disorder that causes overwhelming daytime drowsiness, and ADHD. The FDA added that patients who take carbinoxamine maleate instead of Zenzedi will experience undertreatment of their symptoms. Patients can also have a potentially deadly elevated risk of accidents or injuries and may have drowsiness, increased eye pressure, urinary obstruction and thyroid disorder, among other symptoms, according to the FDA’s recall notice.                                            “Patients who take carbinoxamine instead of Zenzedi® will experience undertreatment of their symptoms, which may result in functional impairment and an increased risk of accidents or injury,” the FDA wrote in a notice about the recall. “Patients who unknowingly consume carbinoxamine could experience adverse events which include, but are not limited to, drowsiness, sleepiness, central nervous system (CNS) depression, increased eye pressure, enlarged prostate urinary obstruction, and thyroid disorder.” Azurity Pharmaceuticals sent recall notification letters to drug wholesalers on January 4 via an overnight letter and has arranged for the return of all affected product at the wholesale level. The company said that no reports of serious injury have been made as a result of the mixup.    The Zenzedi recall comes in the midst of a nationwide shortage of medications used to treat ADHD. The shortage has been affecting supplies of the drug Adderall since a manufacturer experienced production delays in Fall 2022, according to a report from CNN. At least 11 manufacturers of Adderall or generic versions of the drug were listed on the FDA’s shortage list in September 2023. The shortage of ADHD medication has left many patients struggling to fill their prescriptions, according to healthcare professionals.  “A lot of the young people that I’ve been treating have had difficulties getting their medications month to month,” Dr. Warren Ng, a professor of psychiatry at Columbia University Medical Center who also serves as president for the American Academy of Child and Adolescent Psychiatry, told CNN. When taking their prescribed medication, many patients with ADHD are able to function better. But when they run out of their medication, it can have a tremendous impact on their self-esteem. “I’ve seen kids who want to drop out of school, don’t want to continue with their educational path or drop out of college suddenly making the honor roll,” Ng said. And “instead of seeing, being seen as being lazy or dumb or slow, they can envision themselves really utilizing all of their mental, psychological and intellectual abilities to really see themselves for who they are, which is so much more.”

https://hightimes.com/

Connecticut Legal Loophole Allows THC Seltzers at Liquor Stores

Liquor stores in Connecticut—not licensed cannabis retail stores—are selling THC-infused drinks such as seltzers legally, due to a legal loophole regarding dosages listed on the cans. Cannabis retail stores are selling cans listed as one serving, but the same cans of cannabis-infused seltzer, usually running in sizes from 7.5 – 12 ounces, are labeled as five servings in a package at a liquor store or market. All they have to do is ensure that each serving contains less than 1 mg of THC per serving and they can sell the seltzers without violating state law. CT Insider reports that when the drinks are labeled as five servings rather than one, they are technically legal to be sold anywhere in the state, so long as other elements of the packaging are in line with state rules. “You can sell that in a local convenience store. It’s a seltzer. It doesn’t have any alcohol in it. It is a non-alcoholic beverage,” said Larry Cafero, Wine & Spirits Wholesalers of Connecticut executive director, and former Republican leader in Connecticut’s House of Representatives. “The manufacturer, in order to get around a Connecticut law, is creating stickers that turns a 12-ounce can that they had initially labeled as one serving into multiple servings, so that they could comply with the THC-per-serving standard.” “So, we have this little loophole,” he said. State authorities confirmed they are operating within the scope of law. Connecticut’s Department of Consumer Protection (DCP) clarified that the drinks are indeed legal. “A package containing less than 1 milligram of THC per serving and less than 5 milligram per package is not considered cannabis, and may be produced and sold without a license,” DCP spokesperson Kaitlyn Krasselt confirmed.  Connecticut legalized adult-use cannabis in 2021 and later became available for purchase by adults at retail outlets in January 2023. Connecticut Governor Ned Lamont signed legislation to legalize adult-use cannabis in June 2021, ending the prohibition on possession of cannabis by adults 21 and older and creating a framework for regulated adult-use cannabis sales. The bill also included restorative justice and social equity measures, including provisions that led to the expungement of nearly 43,000 marijuana-related convictions.  “This is constantly evolving, and we realized as a committee that we’ve got to get further ahead of this so that’s why this session we’re going to be changing that definition to make it even just a more bright line rule,” said state Rep. Michael D’Agostino (D-Hamden), who is also chairman of the legislature’s general law committee.  The current plan is to drop the THC limit to .5 mg per container, D’Agostino said. Any products containing more THC than that would only be available in licensed cannabis retail outlets. “The question is, what is cannabis or not cannabis right now? The products that do not meet the definition, i.e. under 5 milligrams of THC per container, are not cannabis and therefore they’re not subject to the cannabis laws,” D’Agostino said. “But once we change this and lower the threshold, even more of those laws will apply.” DCP issued further guidance recently to liquor stores in the state, clarifying that while THC-infused seltzers are legal to sell, they cannot be labeled as “cannabis.” That includes seltzers labeled as “canna-beverage.” As a result, some liquor stores began removing products from their shelves after receiving the guidance.  The legislative session convenes Feb. 7. Cannabis consumers in the state are now able to purchase larger amounts per transaction. Connecticut’s cannabis regulatory agency announced in November 2023 that it is increasing the amount of cannabis that can be bought in a single transaction by doubling the state’s limit on recreational marijuana purchases. Under the new regulations approved by the Connecticut DCP, adult-use cannabis consumers will be permitted to purchase up to a half-ounce, or about 14 grams, of cannabis flower or its equivalent beginning in December 2023.  Medical cannabis in the state is another story. The limit on purchases of medical cannabis has not been changed. It remains at 5 ounces of cannabis flower or the equivalent monthly, with no limits on purchases in a single transaction. “DCP has continually reviewed available supply and demand since prior to the launch of the adult-use cannabis industry in January 2023,” DCP Commissioner Bryan T. Cafferelli said in a statement. “As more retailers, production companies and other supply chain licensees have come online, the capacity of the industry has increased. We are confident this measured approach to adult-use sales has resulted in a healthy market for businesses, and a safe and fair marketplace for adult-use cannabis consumers and medical marijuana patients.” Details are being ironed out regarding where cannabis seltzers can be sold in the state.

https://hightimes.com/

DEA Re-Hires Agent Who Was Fired for Taking CBD

The Department of Justice has rescinded a DEA decision to fire a special agent who was let go due to a positive reading for CBD on a drug test. DEA special agent Anthony L. Armour will be re-hired as a special agent and be reimbursed for back pay and legal expenses after a years-long court battle that stretches back to 2019 when a routine drug test showed he had been using CBD, which Armour maintained in court was for the purpose of treating chronic pain in lieu of highly-addictive opioid based painkillers. “I’m excited to be getting back to work at DEA,” Armour said to The New York Times. “I hope to finish my career at DEA by helping its mission in taking dangerous drugs like fentanyl off the streets.” Armour’s battle with chronic pain goes back to an injury he sustained during his college football career. He was also injured on the job as a DEA agent in a car crash during a surveillance operation, after which he suffered from back pain and a sprained neck. He ordered CBD products and a vaporizer from the internet, under the impression that he was not taking any illegal risks as the 2018 Farm Bill federally legalized hemp products.  “For Armour and many others in this country, this change meant new opportunities—particularly as to CBD, a non-THC cannabinoid in the cannabis plant,” a portion of the lawsuit said. “Armour hoped CBD oils could play a role in his pain management. That he did is unsurprising. From Martha Stewart to Wrigley Field, CBD has become embedded in American culture.” After he failed the drug test, Agent Armour turned the CBD products he had ordered into his superiors. Under federal law, hemp-derived products are defined as such if they contain less than 0.3% THC (please follow these handy-dandy little hyperlinks if you want more information on the clusterfuck of loopholes the Farm Bill created with regard to hemp-derived cannabis products). Of the three different hemp-based products Agent Armour turned in, court documents showed that two of them tested within the 0.3% THC range but one of them tested above the allowed threshold at 0.35%, which could be due to the notoriously unreliable potencies of hemp products and the methods by which they are tested. The DEA even went so far as to double down on their decision years into the lawsuit in late August of 2023. They filed a court brief defending Agent Armour’s termination just days before the Department of Health and Human Services officially recommended the federal rescheduling of cannabis from Schedule 1 to Schedule 3. The DEA also issued an official notice to all DEA employees after Armour’s termination to avoid all CBD products despite their federally legal status. “Mr. Armour was an outstanding DEA agent when he took a chance in 2019. He believed it was unlikely that CBD products would cause him to test positive for marijuana, but he knew it was possible, and he bought those unregulated products on the internet and consumed them anyway,” the DEA brief said. “Mr. Armour argues that he ‘displayed negligence or poor decision-making,’ and DEA properly held him accountable for his poor decisions when they resulted in a verified positive drug test. DEA lost trust in Mr. Armour and properly removed him.” Despite a years-long fight to keep Agent Armour off the payroll the DEA has agreed to reinstate him and pay him $470,000 in back pay and legal fees, according to the New York Times who obtained a copy of the court filings from earlier this month. Agent Armour told the New York Times he still sees value in using CBD for pain management but that he will consult a medical professional for viable alternatives upon his return to work.  “Federal drug testing policies—and importantly, attitudes about drug testing—have not caught up with the times. I’m not the only career law enforcement officer in this country with chronic pain, nor am I the only law enforcement officer that has turned to legal cannabis products to address pain,” Agent Armour said in court testimony in September. “Nobody should have to choose between suffering pain and serving our country.”

https://hightimes.com/

‘Peaky Blinders’ Paul Anderson Slapped with Fine in Drug Possession Case

Arthur Shelby is a troubled soul. The Peaky Blinders character must live under his younger brother, Thomas Shelby’s shadow, and deal with often hard-to-watch, but somehow, relatable, acts of violence, towards both others and himself, self-medicated with drugs and Jesus. And based on recent headlines (in the real world), it appears that, at least for some of such, the actor who plays Arthur, Paul Anderson, opts for Method acting, which aims to foster genuine portrayals by immersing oneself in and embodying the internal motivations and emotions of a character. So, basically, acting like the character off screen as well as when the cameras are rolling.  As The Guardian reports, Anderson has been fined for possession of drugs. These include crack cocaine, amphetamines, in addition to prescription substances, diazepam (Valium) and pregabalin. The incident occurred on Boxing Day, the party-fueled British holiday that is held the day after Christmas. His lawyer claims that the actor uses the drugs to break into character to please fans who recognize him.  Where did Anderson land himself into trouble? At his local pub, of course, who contacted the coppers after the bar’s manager noticed “crack cocaine fumes coming from the disabled toilet after the actor walked out,” MailOnline reports. He was with a friend and his baby.  On Thursday, the 48-year-old actor stood before Highbury Corner magistrates court, facing charges of possessing class A crack cocaine, class B amphetamines, and two types of class C prescription drugs. He admitted to all four counts, resulting in a total fine of £1,345. Reports indicate that Anderson only spoke to acknowledge his pleas and to verify his identity and north-west London address. Anderson’s attorney, addressing the court in mitigation, reportedly stated: “You will recognise the defendant from a very intense part that he has played in a recent television programme. He is often recognised and does his best to please fans of the show by slipping into character. “He was recognised that Boxing Day and tried to play up for these people. And because of the lifestyle he leads people often give him inducements.” The lawyer further noted that Anderson had not been using crack cocaine, but conceded: “He has found himself in an unfortunate position and should have had the strength to say no.” While this news is hard not to pass on for all the Peaky Blinders fans, there’s a lot to unpack that’s not so funny. First, turning to the U.S., if you want to get angry, remember that while cannabis remains a Schedule I substance, cocaine (even though the sentencing guidelines have historically been much harsher, as the result of laws that tend to lock up more poor than rich folks), is only a Schedule II. And, while we don’t know the exact details of how and when Anderson was using, any stimulant as strong as crack, for the sake of one’s health, should not be paired with amphetamines.  Diazepam, the brand name of Valium, is a benzodiazepine. It’s in the same anti-anxiety drug class as pills such as Xanax, Klonopin, and Ativan. When benzodiazepines hit the market in the 1960s, chemists thought they’d cured anxiety. However, as is becoming increasingly reported, unlike cannabis for anxiety, such medications are just too easy to develop a physical dependence on when used other than prescribed, which is as-needed, or on a short-term basis.  While, if you want to take a tolerance break from cannabis, while you might miss it, one can just put down the herb and not think too much about it, with benzos, suddenly stopping them after continued use is no joke, like, comes with risks of seizures if not done correctly. As detailed in the Ashton Manuel, the bible for getting off of benzos, if one is weaning off something like Xanax or Klonopin, it’s actually recommended to switch to Valium and then slowly taper off as it’s less potent and has a longer half-life. As High Times reported, Sub-anesthetic ketamine infusions, which are already used for treatment-resistant depression (TRD), may also help people through benzodiazepine withdrawal, new research published in Neuropsychopharmacology shows. However, of the substances found, MailOnline reports that Anderson later tested positive for opiates and cocaine (not crack cocaine), the court heard, so while there’s possession charges, we have no idea of the actor’s personal use or medication schedule. But we’re on your side, Arthur Shelby. 

https://hightimes.com/

Cannabis Ballot Initiative Title Rejected by Arkansas Attorney General

Arkansas Attorney General Tim Griffin recently rejected a medical cannabis ballot measure because of its title. The Arkansas Medical Cannabis Amendment of 2024 was submitted on Jan. 12 by Stephen Lancaster of the law firm Wright Lindsey & Jennings LLP. Griffin responded to the submission, although the opinion was initially prepared by Assistant Attorney General William R. Olson on Jan. 29, explaining the reasoning behind his decision to reject the measure in its current form. He clearly states in the beginning of this letter that his decision is not a reflection of his support or opposition to this ballot measure, or any others. “My decision to certify or reject a popular name and ballot title is unrelated to my view of the proposed measure’s merits,” Griffin began. “I am not authorized to consider the measure’s merits when considering certification.” However, ballot titles are required to be written in a very specific way. Those who write the measures must ensure that the titles contain all of the essential facts “which would give the voter serious ground for reflection,” but also attempt to keep it brief. “The ballot title is not required to be perfect, nor is it reasonable to expect the title to address every possible legal argument the proposed measure might evoke,” Griffin explained. “The title, however, must be free from any misleading tendency—whether by amplification, omission, or fallacy—and it must not be tinged with partisan coloring. The ballot title must be honest and impartial, and it must convey an intelligible idea of the scope and significance of a proposed change in the law.” Griffin continued to share the core reason behind the rejection, explaining that the title was not formatted properly and contained ambiguous statements. “Where the effects of a proposed measure on current law are unclear or ambiguous, I am unable to ensure the popular name and ballot title accurately reflect the proposal’s contents until the sponsor clarifies or removes the ambiguities in the proposal itself.” Griffin is sending the ballot measure authors back to the drawing board to fix the wording. The header, for instance, currently reads “Be it Enacted by the People of the State of Arkansas,” but wording including “enacting clauses” is only required for bills, not constitutional amendments, which may cause voters to be unsure if this is a bill or a constitutional amendment. He also suggested new text to a section that discusses advertising, and ambiguous wording for “rules shall also require child-proof packaging,” addresses that “medical cannabis” as a phrase is not defined anywhere, noting that the interchangeable use of “marijuana plants” and “cannabis plants” be just “cannabis plants” to avoid confusion, and more. If the Arkansas Medical Cannabis Amendment of 2024 is passed, it would amend the constitution to allow patients and caregivers to cultivate up to seven mature cannabis plants, as well as seven younger plants, expand the qualifying conditions of medical cannabis to include more than the current 18 conditions, allow out-of-state patients holding medical cannabis cards to purchase cannabis in Arkansas, remove fees for cannabis card applications, and allow those cards to last for three years instead of one. It also includes a section entitled “Effect of future federal classification of marijuana” which would permit possession of up to one ounce of cannabis if the federal government decides to remove cannabis from the list of controlled substances. The Arkansas Advocate published an article on this topic and noted that the advocate group can only begin collecting signatures once Griffin has signed off on a ballot measure. After that, they have until July 5 to submit 90,704 signatures in order to qualify for the ballot in November. Erika Gee, an attorney representing Arkansans for Patient Access, shared a statement with the news outlet regarding what’s next. “Arkansans for Patient Access is reviewing Attorney General Tim Griffin’s ballot proposal opinion. We intend to address the issues raised and resubmit,” Gee said. “We are confident ballot language will be presented that ultimately gains approval.” Arkansas voters legalized medical cannabis in November 2016 through Amendment 98, and sales began in May 2019. In August 2022, a recreational cannabis ballot initiative from Responsible Growth Arkansas was rejected because of its name and title. The group quickly filed a lawsuit  “to challenge the State Board of Election Commissioners’ thwarting of the will of the people and their right to adopt laws by initiative.” The Arkansas Supreme Court said that the measure would still appear on the ballot, as Arkansa Issue 4. However, in November 2022, 56.25% of voters voted no, while only 43.75% voted yes. Late last year, the Arkansas Medical Marijuana Commission announced that medical cannabis taxes were helping to fund kids’ school lunches in the state. The commission stated that while the state collected $115 million from cannabis taxes, an estimated $87 million was granted for food insecurity.

https://hightimes.com/

Alaska Lawmaker Introduces Psychedelics Task Force Bill

An Alaska lawmaker has introduced a bill to create a task force to study the potential medical uses of psychedelic drugs including psilocybin and MDMA. The legislation, Senate Bill 166, was introduced earlier this month by Democratic state Senator Forrest Dunbar. If passed by the legislature and signed into law by Republican Governor Mike Dunleavy, Dunbar’s bill would establish a task force that would be given one year to study how psychedelics might be used to address Alaska’s mental health challenges. The task force would investigate paths to legalize psychedelics, requirements for licensing and insurance, and barriers to access to the drugs. “We want Alaska to have a regulatory framework to potentially allow medical providers to use the substances, which had been shown in sort of the early data of the tests to potentially have really positive impacts on people dealing with trauma and with addiction,” Dunbar said in a statement, according to a report from Alaska Public Media.  The psychedelics task force created by the legislation would consist of people representing the healthcare needs of Alaska Natives, military veterans and survivors of domestic abuse and sexual assault. Dunbar said it is important to include Alaska Natives in the task force, noting that other states have not included representation of Indigenous communities and traditional healers in their discussions about psychedelics policy reform. Dunbar introduced Senate Bill 166 in anticipation of a potential change in the legal status of psychedelic drugs at the federal level. Clinical research and other studies into psychedelics such as psilocybin and MDMA have shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, PTSD, substance misuse disorders and anxiety.  “It doesn’t work for everyone, but there are certainly people who could access these substances and potentially have life changing medical results,” Dunbar said. Research published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. A separate study published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. In 2017, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for psychotherapy utilizing MDMA, the psychedelic drug commonly known as Ecstasy, indicating that the therapy is a significant improvement over existing treatments. Last month, MAPS Public Benefit Corporation (MAPS PBC), a subsidiary of the groundbreaking psychedelics nonprofit advocacy group the Multidisciplinary Association for Psychedelic Studies (MAPS), announced it had submitted an application seeking FDA approval for MDMA-assisted therapy. Only weeks later, the organization announced it had changed its name to Lykos Therapeutics and had raised $100 million in financing to develop psychedelic therapies. As the research continues, Dunbar said it is important to address psychedelics policy including current prohibition and potential legalization so the drugs will be available to people who can benefit from them. “The hope is because these are medical treatments that we would find a way to bill insurance like anything else,” Dunbar said. “How do we make sure we can bill Medicaid and bill private insurance? And I know the indigenous community in particular needs to think about, and will help guide the task force, so that we can make sure we’re getting funds into the traditional healers’ hands as well.” Melissa Bradley, an epidemiologist based in Anchorage who studies psychedelic medicines, said that she became interested in the field after seeing the strong research data. She notes that psychedelic therapy is not an easy undertaking. Many patients find the experience challenging or upsetting during treatment, but long-lasting improvements in mental health have been reported for many patients.  Most research into the therapeutic potential of psychedelics is conducted in a controlled environment. Although the method is effective, finding ways to use the drugs in other, less controlled settings could be the key to greatly expanding access to psychedelic therapy.  “To really figure out the mystery of psychedelics is figuring out the mysteries of consciousness,” Bradley said. “And, we’re kind of poking at that, on the research side of things, but it’s also moving forward, in terms of policy. And so, it will be kind of a Wild West in terms of policy and regulations.” Dunbar’s bill has been referred to the Senate Labor and Commerce Committee for consideration. Democratic State Representative Jennifer Armstrong has filed companion legislation to Senate Bill 166 in the Alaska House of Representatives, where the measure has been assigned to the Health and Social Services Committee. No hearings have yet been planned for the bills, but Dunbar said he hopes to have one scheduled for early February.

https://hightimes.com/

Psilocybin Treatment Bill Proposed in Hawaii

A new bill was introduced in Hawaii last week on Jan. 24, which aims to establish a regulatory framework for therapeutic psilocybin if passed. However, in its current form, the bill would help protect patients who choose that form of medicine, rather than fully legalize psilocybin. Senate Bill 3019 was introduced by Sen. Chris Lee on Jan. 24, and a companion bill, House Bill 2630, was introduced on Jan. 23 by 14 representatives. “…the purpose of this Act is to ensure that people who struggle with trauma and treatment-resistant mental health ailments are not penalized by the State for the use of psilocybin for therapeutic purposes when the patient’s licensed mental health professional provides a professional recommendation that the benefits of therapeutic use of psilocybin would likely outweigh the health risks for the qualifying patient,” the bill stated. Additionally, should any psilocybin products or paraphernalia be seized by law enforcement and a defendant proves in court that they consume legally through the program, law enforcement would be forced to return the products. However, if any patient attempts to claim they use psilocybin for therapeutic purposes to avoid arrest, they will be charged $500. According to SB 319, the benefits of the bill would be limited to those who have a high school diploma or equivalent degree, are currently 21 years or older, must be a resident in Hawaii, and would have to undergo a “psychedelic integration training program” that has been approved by the Office of Wellness and Resilience (OWR). Once a person qualifies, they could potentially gain access to psilocybin treatment if they suffer from any of the following conditions: “post-traumatic stress disorder (PTSD), treatment-resistant depression or major depressive disorder, end-of-life anxiety, existential stress, and demoralization, anorexia, bulimia, and other eating disorders, addiction, obsessive compulsive disorder.” Additionally, other mental health conditions could also qualify for psilocybin if it’s approved by the Department of Health and requested by a licensed mental health professional. Therapy sessions would be structured in three phases. First, the preparation session, which would allow the patient to meet with a facilitator. Second, the administration session, where the patient “purchases, consumes, and experiences the effects of psilocybin” while the facilitator supervises. Finally, an integration session would be held, which would allow the facilitator to offer care for the patient and inform them about peer support and other resources that could be beneficial to them. The OWR announced in August that the Breakthrough Therapies Task Force held its first meeting on Aug. 29, 2023. Its role is to prepare how to implement therapeutic programs that include MDMA and psilocybin. Lee is one of the members, in addition to 10 others, who are members of the task force. Hawaiian legislators’ approach to psilocybin treatment is much different than the way similar laws have been crafted in states such as Oregon and Colorado. The first psilocybin treatment center to be licensed and to begin operating in Oregon, EPIC Healing Eugene, had thousands of people waitlisted just three months after it opened in June 2023. An end of year report stated that by the end of 2023, more than 700 people had experienced psilocybin at treatment centers across the state. Colorado’s psychedelics bill was passed by voters in 2022 and signed by Gov. Jared Polis in May 2023. It removed criminal penalties for possession and consumption of substances such as psilocybin, ibogaine, mescaline, and DMT. These substances can also be shared (ibogaine is the only exception), but not sold, and it permits the home cultivation of mushrooms within a 12 x 12 foot space. In November 2023, Hawaii Attorney General Anne Lopez announced a 294-page plan to legalize adult-use cannabis. The proposal included a 4.25% excise tax on adult-use products, plus a 10% tax on surcharge. It also included a way for illegal cultivators to enter the legal industry by providing grants through a social equity program. “The most important thing we can do is we can bring the people who have been growing and selling marijuana illegally into the legal market,” Lopez said. Medical cannabis dispensaries that have already gone through the hurdles of licensing would be among the first to sell in a recreational market. “They’re already standing up, they’re already growing, they are already prepared to go to market,” Lopez explained. Some legislators expressed their approval of Lopez’s proposal late last year, including House Judiciary Chair David Tarnas. “The attorney general has done a really good job pulling together all of the different input and providing a comprehensive bill,” Tarnas said. Sen. Jarrett Keohokalole called it “the best version to date. And part of it is the efforts to try and address a lot of the issues that came up along the way.”

https://hightimes.com/

Leaders, International Authorities Unite After Historic Fiji Drug Bust

Police seized nearly five tons of methamphetamine in Fiji, equivalent to more than $2 billion in Fijian dollars (approximately $886.2 million USD). The first Jan. 14 raid resulted in seizure of more than three tons of meth at a warehouse on the western side of Fiji’s main island near the country’s main international airport, according to an OCCRP report. The second raid took place Jan. 20, with Fiji’s public prosecutor sanctioning charges against 13 people in connection to the raids, RNZ reports. Those accused have been charged with unlawful possession of illicit drugs, according to a statement from the Office of the Director of Public Prosecutions (ODPP). “Of the 13 accused persons, two are also charged with unlawful importation of illicit drugs. It is alleged that the accused persons without lawful authority, facilitated the importation and were found in possession of 4.8 tonnes of methamphetamines, an illicit drug, the statement says. The ODPP also said that three of the 13 suspects were also charged with possession of property suspected of being proceeds of crime. “It is alleged that the three accused persons were found in possession of cash (local and overseas currency) suspected of being proceeds of crime,” the statement said. One of the 13, Justin Ho, was previously charged for exporting 2015.7 grams of cocaine from Sydney in 2018 while working as a flight attendant for Fiji Airways. Ho, and the other suspect, ended up walking free after the drugs went missing from the Namaka Police Station and the ODPP filed to discontinue proceedings. A Fijian police officer was also charged in relation to the incident, after allegedly scooping up what was believed to be crystal meth powder from the first drug bust. The officer also allegedly fled the scene on Jan. 14 and was apprehended two days later. A Fiji court proceeded to grant bail to the 13 people charged after questioning and holding them in custody for 48 hours per country law. They are still under a curfew and must appear at the Lautoka High Court on Friday.  Fiji Police are now working with their nearby counterparts, like the Australian Federal Police and the Pacific Transnational Crime and Coordination Centre, and expect to make additional arrests. According to Fiji Police Assistant Police Commissioner Mesake Waqa, the drugs arrived in Fiji in late December and the country was “being used as a transit point and that the methamphetamine was destined for a foreign market.” Waqa also said that the exchange of the meth shipment was believed to have been made outside of the country’s Exclusive Economic Zone, and the packages were delivered through a barge. “The Fiji Police Force will not be making further comments on the ongoing investigation until major developments are made,” Waqa said. According to the Fiji Sun, three chiefs — Tui Nadi Ratu Vuniyani Navuniuci, Tui Sabeto Ratu Viliame Mataitoga and Tui Nawaka Ratu Joeli Naevo — have also united to address the issue and naming their concern about drugs in the country. It’s looking as though this incident could ignite a War on Drugs in the region, as entities like the Nadi Chamber of Commerce and Nadi Town Council also urged for swift action to address what they called a “serious and worrying issue.”  Dr. Ram Raju, president of the Nadi Chamber of Commerce and Industry, said that these drug busts were staggering and that Fiji is vulnerable acting as a middle country for illegal drug trade. Raju similarly called for major, sweeping measures, even suggesting that Fiji be deemed as “smoke and drug free.” Pio Tikoduadua, Fijian Parliament minister and member, pointed to the need for legislative review and strengthening the country’s laws around illicit drug trade and border control. Tikoduadua also called for harsher penalties on those involved in the drug trade and building effective processes for police investigations while emphasizing that education is one of the best tools to discourage Fijians from using drugs.

FAQ: How to use this hemp news hub

What topics does Chow420’s hemp news cover?

We aggregate and surface reputable coverage on hemp laws and enforcement, THC thresholds and policy proposals, cannabinoid products (CBD/Delta-8/hemp-derived THC), compliance, lab testing, recalls, and broader industry news.

Is this legal advice?

No. This page is for news and education. Hemp rules can change quickly and vary by state—always verify against the latest official guidance and consult qualified counsel for compliance decisions.

How do I evaluate hemp product safety claims?

Look for current third‑party COAs (Certificates of Analysis), clear ingredient labeling, and transparent sourcing. Be cautious with vague potency claims or missing lab reports.

Why do some articles mention Delta‑8 or “hemp-derived THC”?

These products often sit at the center of policy and enforcement changes. We track major updates so shoppers and brands can understand evolving requirements and market impacts.

How often is the news updated?

The crawler is scheduled to run daily. New items appear as sources publish updates.